Redifferentiation therapy for thyroid cancer.
Thyroid tumorigenesis and carcinogenesis accompany progressive loss of thyroid-specific differentiated functions. Some thyroid cancers are or become dedifferentiated, and they become refractory to efficacy-proven conventional therapies such as radioiodine ablation therapy and thyrotropin (TSH)-suppressive therapy. Redifferentiation therapy by either redifferentiating agents or gene transfer of differentiation-related genes may retard tumor growth and make tumors respond to conventional therapies.
Park
Jin-Woo
JW
Department of Surgery, College of Medicine, Chungbuk National University, San 62 Kaeshin-dong, Heungdok-gu, Cheongju, 361-763 South Korea.
Clark
Orlo H
OH
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D010648:Phenylacetates / Q000627:therapeutic use; D010654:Phenylbutyrates / Q000627:therapeutic use; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists; D000077185:Resveratrol; D012176:Retinoids / Q000502:physiology; D013267:Stilbenes / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000473:pathology* / Q000503:physiopathology / Q000628:therapy*; D014157:Transcription Factors / Q000819:agonists
D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D056572:Histone Deacetylase Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010648:Phenylacetates; D010654:Phenylbutyrates; D018160:Receptors, Cytoplasmic and Nuclear; D012176:Retinoids; D013267:Stilbenes; D014157:Transcription Factors; C025136:phenylacetic acid; D000077185:Resveratrol